name: ocr-PIRA-cohort
title: Longitudinal clinical data in Ocrelizumab-treated multiple sclerosis patients
description: >-
  A clinical dataset of ocrelizumab treated multiple sclerosis patients at the HHU University
  Clinic Düsseldorf with routinely collected clinical, imaging and OCT results (no imaging data).
  Data was collected for routine visits from 2018 to 2022.
landing_page: https://data.abcd-j.de/dataset/db7592d0-6206-5684-a29c-8059a6033241/0.1.0
version: 0.1.0
modified: 2023-03-01
keyword:
  - clinical data
  - multiple sclerosis
  - ocrelizumab
  - PIRA
  - EDS
was_attributed_to:
  - meta_type: dlco:ResearchContributorObject
    meta_code: jensingwersen
    name: Jens Ingwersen
  - meta_type: dlco:ResearchContributorObject
    meta_code: larsmasanneck
    name: Lars Masanneck
    email: lars.masanneck@med.uni-duesseldorf.de
    orcid: 0000-0003-2496-1415
    address: Geb. 13.53, Moorenstraße 5, 40225 Düsseldorf
  - meta_type: dlco:ResearchContributorObject
    meta_code: marcpawlitzki
    name: Marc Pawlitzki
  - meta_type: dlco:ResearchContributorObject
    meta_code: sarasamadzadeh
    name: Sara Samadzadeh
  - meta_type: dlco:ResearchContributorObject
    meta_code: margitweise
    name: Margit Weise
  - meta_type: dlco:ResearchContributorObject
    meta_code: orhanaktas
    name: Orhan Aktas
  - meta_type: dlco:ResearchContributorObject
    meta_code: svengmeuth
    name: Sven G. Meuth
  - meta_type: dlco:ResearchContributorObject
    meta_code: philippalbrecht
    name: Philipp Albrecht
qualified_attribution:
  - agent: jensingwersen
    had_role:
      - marcrel:aut
  - agent: larsmasanneck
    had_role:
      - marcrel:aut
      - dpv:DataController
  - agent: marcpawlitzki
    had_role:
      - marcrel:aut
  - agent: sarasamadzadeh
    had_role:
      - marcrel:aut
  - agent: margitweise
    had_role:
      - marcrel:aut
  - agent: orhanaktas
    had_role:
      - marcrel:aut
  - agent: svengmeuth
    had_role:
      - marcrel:aut
  - agent: philippalbrecht
    had_role:
      - marcrel:aut
relation:
  - meta_type: dlco:PublicationObject
    meta_code: ingwersen_etal
    citation: >-
      "Ingwersen, J., Masanneck, L., Pawlitzki, M. et al. Real-world evidence of ocrelizumab-treated
      relapsing multiple sclerosis cohort shows changes in progression independent of relapse
      activity mirroring phase 3 trials. Sci Rep 13, 15003 (2023)."
    doi: https://doi.org/10.1038/s41598-023-40940-w
qualified_relation:
  - had_role:
      - CiTO:isDocumentedBy
      - CiTO:citesAsAuthority
    entity: ingwersen_etal
distribution:
  meta_type: dlco:FileContainerObject
  meta_code: ./
  has_part:
    - meta_type: dlco:DigitalDocumentObject
      meta_code: cPIRA_OCR_ps_220918_w_CD19
      byte_size: 62318
  qualified_part:
    - name: cPIRA_OCR_ps_220918_w_CD19.xlsx
      relation: cPIRA_OCR_ps_220918_w_CD19
# "usedFor": {
#     "@type": "http://www.w3.org/ns/prov#Activity",
#     "title": "Progression independent from relapse in ocrelizumab-treated relapsing multiple sclerosis cohort"
# },
# "sampleOrganism": "NCBITaxon:9606",
# "samplePart": "UBERON:0000955",